Harmony Biosciences’ $60 million bet on a once-failed Fragile X candidate has gone off the rails. Two years after picking up ZYN002 despite a midphase flop, the biotech has reported that a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback